Beclin-1 Activator II, retro-inverso TAT-Beclin-1

A cell-permeable, all-D-amino acid autophagy-inducing peptide based on the retro-inverso sequence of Tat-Beclin1 (Cat. No. 506048) that is expected to be more resistant to proteolytic degradation than Tat-Beclin1 and is shown to be more potent than Tat-Beclin1 in inducing autophagy in muscle, heart, and pancreas tissues in 6-wk-old GFP-LC3 transgenic mice (1.94-, 1.48-, and 1.16-fold of Tat-Beclin1 GFP-LC3 induction potency in respective tissue in 6 h; 20 mg/kg i.p.) in vivo. Only the retro-inverso peptide, but not Tat-Beclin1, is effective in reducing autophagy substrate p62 level in the brain tissue of 5-d-old neontal GFP-LC3 mice (20 mg/kg i.p.). The retro-inverso peptide treatment is also reported to greatly reduce brain viral titre in neonatal mice subjected to WNV (West Nile Virus) CNS (central nervous system) infection (>1000-fold reduction 6 d post infection; 20 mg/kg/d i.p. beginning 1 d post infection), while being ineffective against WNV CNS infection in mice with monoallelic deletion of the Beclin1 gene Becn1.

Cell permeable: yes

Primary Target
GAPR-1/GLIPR2

Reversible: yes

Packaged under inert gas

Toxicity: Standard Handling (A)

(D)-H-arg-arg-arg-gln-arg-arg-lys-lys-arg-Gly-tyr~Gly-Gly~thr-Gly-phe-glu-Gly-asp-his-trp-ile-glu-phe-thr-ala-asn-phe-val-asn-thr-OH

Supplied as a trifluoroacetate salt.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Shoji-Kawata, S., et al. 2013. Nature.494, 201.

Sold under license of US Patent 8,722,628.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany